Almost 7 years after licensing it from Novartis, Takeda picked up a regulatory green light from Japan's Ministry of Health, Labour and Welfare for its Haemophilus influenzae type B (Hib) vaccine. The vaccine, Vaxem Hib, is approved for use in children aged two months to under 5 years.
Shares of Aratana Therapeutics jumped 25% to $3.99 a share in after-market trading on January 25, after the company announced it had filed for FDA approval of Galliprant (grapiprant), its drug to treat pain in dogs with osteoarthritis. It is Aratana's first FDA filing, and it comes after a turbulent 2015 for the company, which disappointed investors with dashed hopes for its canine lymphoma franchise.
Amgen's take on AbbVie's top-selling inflammation treatment is in line for FDA approval this year, but a patent fight between the two companies could keep it off the market into the next decade.
The governments of India and France have agreed to make up for lost time and said this week they remain committed to restarting free trade negotiations between New Delhi and the European Union that have been stalled for the past three years.
Thanks to an FDA decision over the weekend, Bristol-Myers Squibb's immunotherapy Opdivo has caught back up to Merck's Keytruda in melanoma. And it won a new combination approval from the FDA to boot.
Munich-based radiotherapy company, Brainlab, has invested a $7.5 million Series C financing into Mountain View, CA-based startup Jan Medical. The cash infusion is earmarked for the completion of ongoing clinical trials and submission of its neurological diagnostic software, Nautilus BrainPulse, to regulators.
Shire has resubmitted the once-rejected eye treatment lifitegrast for FDA approval, handing in new data the company hopes will get its self-described blockbuster drug onto the market.
China FDA has approved two HIV therapies that show the combination of local partners and high unmet need might be a winning one for reaching the market quicker.
Prime Minister Narendra Modi has been trying to attract foreign investment with his "Make in India" campaign, but the reality at home was thrown into sharp relief with the news recently that a project to make heart valves in an Indian special economic zone was being stymied because of "pending approvals, delayed clearances and lack of financing options," according to a report by the Economic Times.
Japan's ban on the combination vaccine for mumps, measles and rubella in routine immunizations, a cumbersome bureaucracy, and a lack of vaccine coverage in the country's healthcare program are putting the nation at risk, various officials and researchers claim.